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 Computational and experimental cocrystal screening of Daidzein against six coformers. 
 A novel Daidzein-4,4’-Bipyridine cocrystal has been discovered and characterised. 
 Cocrystal of Daidzein-4,4’-Bipyridine is connected through intermolecular hydrogen bond 
interactions. 
 The cocrystal of Daidzein-4,4’-Bipyridine shows increased solubility and dissolution rate 
compared to Daidzein. 
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Daidzein (7,4’-dihydroxyisoflavone, DAI) is an isoflavone found in soybeans and Pueraria. DAI has 
potential therapeutic benefits on cancer and osteoporosis yet has quite low solubility, limiting its use. 
Herein a cocrystal screening of DAI with pyridine-derived molecules, i.e., nicotinamide, 
isonicotinamide, caffeine, D-Proline, L-Proline and 4,4’-Bipyridine was conducted. A new cocrystal 
of Daidzein and 4,4’-Bipyridine (DAI-BIP) was successfully generated via grinding and solvent 
methods. DAI-BIP showed an increased solubility and dissolution rate. In comparison to DAI, there 
was a 2.03-fold increase of the dissolution performance parameter for DAI-BIP where the 
concentration observed for DAI quickly reached the equilibrium solubility and continued to reach 
1.49 times DAI solubility. A parachute effect was also observed during the dissolution of DAI-BIP, 
indicating that BIP might be able to maintain the supersaturated state of DAI in solution proving 
DAI’s ability to form cocrystals of higher solubility and enhanced dissolution properties through co-
crystallisation.  
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Flavonoids are a group of polyphenols, which have a 15-carbon skeleton, consisting of two 
aromatic rings connected by a 3 carbon bridges shown in Fig. 1(a). They are common classes of 
nutraceuticals which can be found in fruits, vegetables, cereals, legumes, chocolate, and beverages 
(i.e., tea, coffee or wine) [1, 2]. Flavonoids have shown numerous health and medical benefits, 
including antioxidant, hypocholesterolemic, anti-inflammatory effects as well as the ability to 
modulate cell signalling and gene expression related disease development [3, 4]. Despite their well-
recognised health and medical benefits, flavonoids hold intrinsic physiochemical disadvantages, e.g. 
poor solubility, permeability and inferior stability, resulting in extremely low bioavailability of the 
oral dosage form [2, 3]. In order to increase the bioavailability of flavonoids, various strategies have 
been developed, including absorption enhancers, structural transformation (e.g., prodrugs, 
glycosylation), novel delivery systems (e.g., carries, complexes, nanotechnology, cocrystals), and 
changing the site of absorption (e.g., from large intestine to small intestine) [5, 6].  
In recent years, pharmaceutical cocrystals have drawn a significant amount of interest for their 
ability to modify physicochemical properties of active pharmaceutical ingredients (APIs), in particular  
enhancing solubility and dissolution rate of poorly water-soluble drugs, through supramolecular 
interactions between an API and coformer [7]. Intense effort has been made to design oral form 
nutraceutical cocrystals which have maximized bioavailability and efficacy [8-14]. Selection of an 
appropriate coformer for a given API is key for success in cocrystal design as the coformer can have a 
huge impact on the cocrystals resulting properties. Intermolecular interaction complementarity and 
supramolecular synthon hierarchy are most commonly used as an empirical guideline for the coformer 
selection of cocrystal design [15-17], although many computational tools have been applied for 
cocrystal screening [18-21]. It has been found that pyridine-derived molecules, such as nicotinamide, 
isonicotinamide, and 4,4’bipyridine, were the highly regarded coformers to cocrystallise with a 
flavonoid, presenting an O-HNarom heterosynthon between an O7 hydroxyl moiety of a flavonoid 
and the pyridyl ring of a coformer [8-14, 22-27] 
Daidzein [7,4’-dihydroxyisoflavone, DAI shown in Fig. 1(b)] is a natural isoflavone compound 
that is abundant in soybean and Pueraria [28]. DAI is of pharmaceutical interest due to its potential 
therapeutic effects against cancer, osteoporosis and inflammation [29, 30]. However, the poor 
solubility (3.01 µg/mL at 35°C in water) of DAI [31] resulted in low oral bioavailability (6.1%) and 
very limited clinical application [32]. So far, there is no DAI cocrystal in the CSD (Cambridge 
Structural Database) reported. Although several daidzein cocrystals were reported, there was no single 
cocrystal successfully grown for its structure determination [33, 34]. Therefore, discovery of new 
cocrystal forms of DAI with their structure determined is extremely important for potential 
development of oral dosage form with improved physicochemical properties. 
 In this work, pre-screening was undertaken using both the CSD multi-component screening and 
molecular electrostatic surface potential tools to determine the probability of cocrystal formation of 




DAI with the pyridine-derived coformers, i.e., nicotinamide, isonicotinamide, L-Proline, D-Proline 
and Caffeine, and 4,4’-bipyridine (Fig. 1c-1h). Experimental screening was conducted by co-grinding 
a 1:1 stoichiometric ratio mixture of DAI and a coformer with or without different solvents for 30 
min. The samples were analysed by PXRD (power x-ray diffraction), FTIR (Fourier transform 
infrared spectroscopy), and thermal analysis (DSC and hot stage microscopy) for confirmation of 
cocrystal formations. It was found that only 4,4’-Bipyridine can form cocrystals with daidzein (DAI-
BIP). Solution evaporation experiments of DAI and BIP were subsequently undertaken to obtain 
single cocrystals suitable for structure determination using single XRD analysis. The pharmaceutical 
relevant properties of solubility curve and dissolution rates of the cocrystals have been evaluated. 
 
Fig. 1: Chemical structures of flavonoid skeleton (a), Daidzein (b), Nicotinamide (c), Isonicotinamide 
(d), 4,4’-bipyridine (e), Caffeine (f), D-Proline (g) and L-Proline (h) 
 
2. Materials and methods 
2.1 Materials 
Daidzein (DAI) (≥97% purity),  Isonicotinamide (INAM), L-Proline (LPRO) and D-Proline 
(DPRO) (all with ≥99% purity)  was purchased from Alfa Aesar (Lancaster, UK). Caffeine (CAF), 
4,4’-Bipyridine (BIP) (≥99% purity), Methanol (MeOH) (HPLC grade), Ethanol (EtOH) (HPLC 




grade), Acetonitrile (ACN) (HPLC grade), Formic Acid 0.25M (HPLC grade), Tetrahydrofuran 
(THF) (extra dry), Chloroform (CF), Acetone (ACE) (reagent grade) and Ethyl Acetate (EtAC) 
(reagent grade) were purchased from Fisher Scientific UK (Loughborough, UK). Nicotinamide (NIC) 
(≥99.5% purity) was purchased from Sigma-Aldrich (Dorset, U.K). Double distilled water (DDW) 
was generated using a Bi-Distiller (WSC044.MH3.7, Fistreem International Limited, Loughborough, 
U.K.) in house and used for the duration of the study. 
2.2 Methods 
2.2.1 0.01 M pH 6.8 Phosphate Buffer solution (PBS) preparation 
pH 6.8 PSB solution (0.01 M) was used as media for solubility and dissolution studies. It was 
prepared according to British Pharmacopeia 2010, i.e., 1.365g of potassium dihydrogen phosphate 
(KH2PO4) was dissolved in DDW and the pH of the solution was adjusted to 6.8 by 1 M sodium 
hydroxide addition.  
2.2.2 Ab initio screening  
An initial cocrystal screening was undertaken by the CSD search (ConQuest v2.0.1) using the key 
words of Daidzein and its molecular structure. Cocrystals of nutraceuticals with similar structures as 
DAI were also searched for selection of potential coformers used in experiments for DAI cocrystal 
screening. The pass or fail of formation of cocrystals of between DAI and a chosen coformer was 
evaluated by the CSD multi-component screening tool (Mercury v4.1.0).  
Furthermore, the probabilities of cocrystal formations of between DAI and coformers were 
calculated using the virtual cocrystal screening tools [18], in which an energy difference was 
calculated based on gas phase molecular electrostatic potential surfaces (MEPSs) of the individual 
compounds (Spartan18, v1.3.0). 
2.2.3 Cocrystal screening via neat grinding (NG) and liquid-assisted grinding (LAG)  
In the screening experiments, a total of 200 mg of DAI and either BIP, NIC, LPRO, DPRO, CAF 
or INAM at a 1:1 stoichiometric ratio was prepared in 15 mL stainless steel SmartSnap™ jars 
containing two 7mm stainless steel grinding balls (Form-Tech Scientific, Montreal, Canada). For a 
LAG experiment, 40 µL of solvent (ACE, ACN, CF, DDW, EtAC, EtOH, MeOH or THF) was added. 
Materials were ground in a Retsch Mixer Mill MM 400 (Retsch, germany) for 30 min at a rate of 25 
Hz at room temperature. DAI with INAM was also subjected to grinding in a 1:2 stoichiometric ratio. 
Samples were left to stabilise for 30 min before characterisation by PXRD and thermal methods. 
2.2.4 Preparation of cocrystal powders and single cocrystal 
Daidzein-4,4’-bipyridine cocrystals (DAI-BIP) in a 1:1 stoichiometric ratio were prepared by 
solvent evaporation (SE). A 1:1 equimolar mixture of DAI and BIP was dissolved in a solvent mixture 
of EtAC and EtOH (87%:13%). Solution was stirred at 50°C until all solids dissolved before being 
left in a fume cabinet for evaporation. The formation of cocrystals was confirmed by PXRD, FTIR, 
DSC and hot stage microscopy (HSM).  




Single cocrystals were also prepared using this method, but the solution was slowly evaporated 
over a period of one month and harvested by natural filtration. Crystals were characterised by single 
XRD, FTIR and HSM. 
2.2.5 Solubility studies  
Apparent equilibrium solubility of DAI was measured by adding excess amount of crystalline 
materials to a small vial containing 20 mL of pH 6.8 PBS, which was kept at 37 ± 0.5°C in a shaking 
water bath at 150 rpm for 24 h. The supernatant was separated from the suspension by a micro centaur 
MSB 010.CX2.5 centrifuge (MSE Ltd., London, U.K.) at 13000 rpm for 1 min. The supernatant was 
then diluted to determine the concentration of DAI by HPLC. The cocrystal solubility was determined 
by measuring the eutectic point of the cocrystals [35]. A series of BIP solutions were prepared in 
pH6.8 PBS at concentrations of 0, 2, 3.8, 4.2, 4.4, 4.6, 4.8, 5, 5.2, 6, 8 mg/mL. Excess amount of DAI 
as added to a small vial with 20 mL of each of the prepared BIP solutions, which were kept in a 
shaking water bath at 37°C ± 0.5°C and a shaking rate of 150 rpm for 24 h. The supernatant of each 
suspension was separated by centrifuge whilst all solid residues were separated by filtration. The 
concentrations of DAI and BIP in the supernatant were analysed by HPLC and UV respectively. The 
solid residues were dried naturally and then analysed by PXRD. The eutectic point of the cocrystals 
was determined by the lowest BIP concentration solution where two solid phases of DAI and 
cocrystal coexisted in equilibrium with the solution.  
All experiments above were repeated in triplicate.  
2.2.6 Powder Dissolution studies 
Powder dissolution experiments of DAI and DAI-BIP were performed under non-sink conditions 
in pH6.8 PBS. All materials were ground using a mortar and pestle and sieved by a 60 mesh sieve 
(below 250 µm) to reduce the effect of particle size on the dissolution rates. Each of dissolution tests 
was carried out via USP Apparatus 2 (paddle) at a speed of 50 rpm in 400 mL of dissolution medium 
maintained at 37±0.5 °C using a PTWS 120D dissolution bath fitted with a variable speed stirrer and 
heater (Pharma Test). The cocrystals used in the dissolution tests had the equivalent amount of the 
parent nutraceutical, i.e., 21 mg of DAI-BIP and 13 mg of DAI. Samples of 1±0.1 mL were removed 
at the predefined time points of 5, 15, 50, 60, 120, 180 and 240 min. Supernatants were separated 
from the samples and analysed by HPLC and UV to determine DAI and BIP concentrations 
respectively. All experiments were repeated in triplicate. 
2.2.7 Cocrystal Characterisation 
1) Powder X-ray diffraction analysis (PXRD) and prediction 
Samples were analysed by a Bruker D2 phaser diffractometer equipped with a LYNXEYE XE-T 
detector (Bruker UK Limited, Coventry, UK). The diffractometer was operated at 10mA and 30 kV. 








A simulated PXRD pattern of DAI-BIP from the single crystal structure was performed using the 
powder pattern tool in Mercury v4.20 (Cambridge Crystallographic Data Centre). Analysis range of 
degrees 2θ was set from 5-40° with a scanning step size of 0.02° (2θ) at a wavelength of 1.54056 Å. 
The pattern was set to include hydrogens. 
2) Single X-ray diffraction analysis (SXRD) 
Measurements were carried out at 125K on an Agilent SuperNova diffractometer equipped with 
an Atlas CCD detector and connected to an Oxford Cryostream low temperature device using mirror 
monochromated Cu Kα radiation (α = 1.54184 Å) from a Microfocus X-ray source. The structure was 
solved by intrinsic phasing using SHELXT1 and refined by a full matrix least squares technique based 
on F2 using SHELXL2014[36, 37].  
All non-hydrogen atoms were located in the Fourier Map and refined anisotropically. All carbon-
bound hydrogen atoms were placed in calculated positions and refined isotropically using a “riding 
model”. Oxygen-bound hydrogen atoms were located in the Fourier Map and refined isotropically. 
3) Fourier-Transform Infrared spectroscopy (FTIR) 
FTIR spectra were collected on an ALPHA interferometer (Bruker UK Limited, Coventry, UK) 
equipped with a horizontal universal attenuated total reflectance (ATR) accessory. Data was collected 
for each sample, between 400-4000 cm
-1
 using 30 scans at a resolution of 2 cm
-1
 by the OPUS 
software at room temperature. 
4) Differential scanning calorimetry (DSC) 
The cocrystal melting point was determined using a PerkinElmer Jade DSC (PerkinElmer Ltd., 
Beaconsfield, UK) operated under a nitrogen atmosphere. The instrument was calibrated using indium 
metal. A heating rate of 20°C/min in a range of 80-360°C was employed for samples (sample mass 
approximately 8mg) in aluminium pans with pinhole lids. 
5) Hot stage microscopy (HSM) 
A Mettler Toledo FP82HT hot stage and FP90 controller (Mettler Toledo, Ohio, United States) 
was used to monitor the thermal events of the cocrystals during heating. The hot stage was connected 
to a Leica DM750 microscope (Leica Microsystems (UK) Ltd, Milton Keynes, UK). Sample was 
prepared on a slide to cover the pinhole of the hot stage. A heating rate of 20°C/min in a range of 80-
360°C was employed for samples. The video of melting was captured on StudioCapture software. 
6) High-performance liquid chromatography (HPLC) 
Concentrations of DAI in solution were analysed using a PerkinElmer series 200 HPLC 
(PerkinElmer Ltd. Beaconsfield, UK) with a HAISLL 100 C18 column (5 μm, 250 ×4.6 mm) 
(Higgins Analytical Inc., Mountain View, CA, USA) at 30°C. An isocratic method with 50% double 
distilled water (including 1% formic acid) and 50% acetonitrile at 0.5 mL/min flow rate and a 
detection wavelength of 248 nm were used to detect DAI concentration.  
7) UV spectroscopy (UV) to detect BIP concentration 




Concentrations of BIP in solution were analysed using a Thermo Scientific Evolution 60s UV 
spectrophotometer (Fisher Scientific UK Ltd. Loughborough, UK) at room temperature. The UV 
spectrometer was blanked using phosphate buffer and samples were analysed at 235 nm. 
 
3. Results and discussion  
3.1 Ab initio screening  
Twenty-five structures were retrieved based on the CSD search using the key words of Daidzein 
and its molecular structures detailed in Table S1 in the supplementary information. There are four 
polymorphs of DAI, with space groups of P21/c,    , P21/n and P212121 [28]. Nine structures 
correspond with solvates or derivatives of DAI. There are no DAI cocrystals deposited. Interestingly 
the other 13 hits are related to Genistein (GEN), another natural isoflavone compound having similar 
molecular structure as DAI [13]. Among them, six GEN cocrystals are found, i.e., Genistein-4,4’-
Biprydine (GEN-BIP), Genistein-L-Proline (GEN-LPRO), Genistein-D-Proline (GEN-DPRO), 
Genistein-Isonicotinamide (GEN-INAM), Genistein-Nicotinamide (GEN-NIC) and Genistein-
Caffeine (GEN-CAF). Therefore, these coformers were selected for screening of DAI cocrystals.  
Based on a pass or fail prediction by the CSD multi-component screening tools, it was found that 
BIP, INAM and NIC can form cocrystals with DAI whereas LPRO/DPRO and CAF failed the initial 
screening (Table S2 in the supplementary information). Furthermore, the probability of cocrystal 
formation between DAI and a coformer selected was calculated using the virtual cocrystal screening 
tools [18]. After geometry optimisation, the MEPSs of DAI and six coformers were generated using 
Spartan18 (v1.3.0) shown in Fig. 2. Potential hydrogen bonding sites of DAI with coformers are the 
two maximal positive potential regions at hydrogens of the hydroxyl groups located at C7 and C4’ 
and two minimal negative potential regions at oxygens located at C1 and C4 on DAI’s MEPS [Fig. 
2(a)]. The difference between the interaction site pairing energies of the potential 1:1 cocrystal and 
two pure compounds and its probability of a cocrystal formation are shown in Table 1. It is shown that 
BIP has the highest probability to form a cocrystals with DAI at 16.70% and Isonicotinamide has the 
lowest probability at 2.48%. However, none of the probabilities is higher than 50%, even with 
variable stoichiometric ratios (the probabilities of formations of 1:2 cocrystals shown in Table. S3 in 
the supplementary information), indicating that all coformers selected are unlikely to form cocrystals 







































Fig. 2:  Molecular Electrostatic Potential Surfaces 
Table 1. Interaction site pairing energy difference and probability of cocrystal formation in a 1:1 
stoichiometric ratio with daidzein 
Coformer Ratio 
Interaction site pairing energy 
difference (∆E), kJ/mol 
Probability of 
formation (%) 
BIP 1:1 -7.02 16.70 
INAM 1:1 -1.90 2.48 
NIC 1:1 -2.56 3.21 
LPRO 1:1 -4.37 6.44 
DPRO 1:1 -4.19 6.02 
CAF 1:1 -6.58 14.42 
 
3.2 Experimental screening  
After computational screening, experimental screening via grinding was conducted. The grinding 
results for DAI-CAF, DAI-DPRO, DAI-LPRO and DAI-NIC were all negative as there was no new 
peak appeared or loss of characteristic peaks of the starting materials of DAI and coformer [Fig. S1 
(i)-(iv) in the supplementary information]. The XRD patterns of ground DAI and INAM mixtures in 
1:1 and 1:2 initially exhibited changes which were thought to be the formation of cocrystals of DAI-
INAM (Fig. S2 in the supplementary information). Yet upon further investigation, it was found to be 
the effect of grinding INAM (Fig. S3 in the supplementary information), no DAI-INAM cocrystal had 
been formed which was consistent with expectation of the low probability of formation (2.48%) in 
computational screening. Screening experiments of 1:1 molar mixture of DAI and BIP showed that 
new crystalline phases of DAI-BIP can be formed by LAG in the presence of 40 µL of solvent of 




EtAC shown in Fig. 3, where key characteristic peaks of DAI disappeared at 6.08°, 8.36°, 15.78° and 
18.86° of 2 and new peaks appeared at 11.51°, 12.67°, 15.04° and 18.24° of 2. The mixture of DAI 
and BIP by LAG in the presence of 40 µL of either ACE, ACN, CF, MeOH or THF also led to DAI-
BIP cocrystal formation confirmed by PXRD patterns in Fig. S4 in the supplementary information. 
There was no cocrystal formation by LAG in the presence of a drop of EtOH and only partial 
transformation was seen in NG shown in Fig. S4 in the supplementary information. Phases of BIP can 
be affected by LAG in the presence of a drop of DDW shown in Fig. S5 in the supplementary 
information, causing the appearance of “new” peaks. The new peaks of the mixture of DAI and BIP 
by LAG in the presence of a drop of DDW belong to the change of BIP new peaks and partial 
transformation to the cocrystals shown in Fig. S4. 
 
Fig. 3: PXRD patterns of DAI (a), BIP (b), DAI-BIP by LAG in the presence of EtAC (c), DAI-BIP 
from solvent evaporation (d), and DAI-BIP XRD simulation (e) 
The XRD pattern of DAI-BIP powders from solvent evaporation is shown in Fig. 3(d), which is 
consistent with that of DAI-BIP by LAG in the presence of EtAC. Cocrystal powders of DAI-BIP 
were prepared by solvent evaporation using a mixture of EtAC (87%) and EtOH (13%) to ensure to 
fully dissolve the components in solution because of the very poor solubility of DAI in EtAC alone. 
The percentage of EtOH in the mixture played a key role for formation of DAI-BIP. It was found that 
the pure cocrystals of DAI-BIP cannot be formed if the percentage of EtOH in the mixture was higher 
than 13%. Effect of the ratio of EtAC and EtOH in the solvent mixture on the formation of DAI-BIP 
was given Fig. S6 in the supplementary information.  




The thermal behaviours of the DAI-BIP powders synthesised were investigated using HSM 
shown in Fig. 4. A cocrystals melting point is usually found to be in between the starting materials 
melting points. DAI displayed a melting activity at 335.3°C and BIP melted at 115.7°C. The high 
melting point of DAI caused BIP to vaporise at a temperature of 197.3°C, HSM allowed visible 
confirmation of the vaporisation. The DAI-BIP showed an endothermic peak at 234°C, which 
corresponded to its melting point in between the original melting points of both DAI and BIP. After 
the DAI-BIP melting at 234°C, two endothermic peaks at 336°C and 344°C were found, 
corresponding to DAI melting point and, potentially, vaporisation of DAI (Fig. 4). The difference in 
the melting point of DAI-BIP is likely due to the change of packing of raw DAI compared to DAI in 
DAI-BIP. It is true that in most cases, cocrystals have different melting points in comparison to the 
individual components, which has been demonstrated to be dependent on their packing and 
stoichiometric ratio [17]. The herringbone packed systems displayed a melting point in between the 
two components as was the case in our study, while the crystal with a channel packing exhibited a 
melting point much lower than both components. Similar results were observed by DSC 
measurements shown in Fig S7 in the supplementary information.  
 
Fig. 4: HSM diagrams of DAI (a), BIP (b) and DAI-BIP via Solvent Evaporation (c) 
 
3.3 Single cocrystal structure analysis 
High quality single crystals of DAI-BIP for SXRD measurements were obtained through slow 
evaporation in a mixture of EtAC (87%) and EtOH (13%). DAI-BIP crystallises as orange coloured 
pinacoidal crystals like that of Rhodonite [Fig. 5(a) and Fig. S9 in the supplementary materials]. The 




crystal structure of DAI-BIP was then determined by single XRD (SXRD) and FTIR analysis (Fig. S8 
in the supplementary) was used to confirm cocrystal formation. DAI-BIP crystallises in the    space 
group of triclinic system with the cell parameters a = 7.9052 (4)Å, b = 10.4920(6) Å, c = 12.1115(7) 
Å and α = 102.434(5)°, β =101.212(5)°, γ =95.900(5)°. The cocrystal asymmetric unit is connected 
through intermolecular interactions between one molecule of DAI and one molecule of BIP (z=2).  
Analysis of the packing in the cocrystal revealed that DAI and BIP were connected through 
O(1)―H∙∙∙N(4’) and O(2)―H∙∙∙N(4) intermolecular interactions, forming a 1D hydrogen-bonding 
chain structure, which extended indefinitely along the a axis in the ab plane. The 1D chain structure 
extends via the b axis via C(2’)―H ∙∙∙ O(2) interactions between one BIP and one DAI molecule to 
form the 2D sheet structure (Fig. 5(c)). The distance between the two chains varied from 3.814 Å to 
5.662 Å, suggesting that the π∙∙∙π stacking interactions amongst the aromatic rings could be ignored. 
The 3D packing structure of the cocrystal (Fig. 5(d)) was formed by extending the 2D structure along 
the ac plane via multiple short contacts between either one DAI and one BIP molecule, or between 
two molecules of BIP. The morphology of the cocrystal was predicted, based on the crystallographic 
data, using the Bravais-Friedel-Donnay-Harker (BFDH) morphology tool from the Mercury software 
(Cambridge Crystallographic Data Centre Mercury v4.20) (Fig. 5(e)). The predicted morphology 
matched well with the experimental single crystal (Fig. 5(a)). Meanwhile, the simulated XRD pattern 
of the cocrystal was shown in Fig. 3(e). It illustrated all the characteristic peaks, which matched with 
what have been measured, including those at 11.50°, 12.27° and 15.00° of 2.  
The SXRD measurements of the DAI-BIP single crystals have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC) with the depositary number 1964859 and the 

















Fig. 5: The structure and packing of DAI-BIP. a) Single crystal under polarised light microscope; b) 
supramolecular synthon; c) 2D packing; d) 3D packing; e) Predicted morphology 
 
3.4 Solubility and dissolution studies  
The solubility and dissolution rate of the cocrystal and its components were examined. It was 
shown that the equilibrium solubility of DAI (i.e. dissolved drug concentration at equilibrium with 
solid drug) was 3.876±0.039 µg/mL (0.0152±1.52 0E-04 mM) in pH6.8 PBS at 37 °C, which is also 
pH-independent (Fig. S10). 
The apparent concentration of DAI was measured in the presence of BIP (Fig. 6(a)) in pH6.8 PBS 
at 37 °C. The apparent concentration of DAI at equilibrium increased when the concentration of BIP 
increased to 3.8 mg/mL, indicating a formation of the DAI-BIP complexes. Within this range, the 
concentration of DAI-BIP hasn’t exceeded its solubility limit, thus there was no precipitation of the 
cocrystal. Therefore, any solid residues observed within such range should be DAI alone, as 
confirmed by PXRD (Fig. 6(b)). When the concentration of BIP was higher than 3.8 mg/mL, the 
apparent concentration of DAI at equilibrium decreased. At a BIP concentration of 4.4 mg/mL, the 
precipitation of DAI-BIP started and two phases, DAI and DAI-BIP, could be observed for the solid 
residues in the solution [Fig. 6(b)]. The concentrations measured for DAI and BIP in the 4.4 mg/mL 
BIP solution represented the transition concentration of DAI-BIP [35], i.e. 0.045 mM for DAI and 
28.171 mM for BIP. So, according to the definition of cocrystal solubility [35],  the solubility of DAI-
BIP was 1.122mM, which was 73.5-fold higher than the solubility of DAI. The higher DAI 




concentration from the cocrystals at equilibrium can be attributed to the improved cocrystal 
dissolution rate and molecular interaction between DAI and BIP in solution. The hydrogen bonding 
between DAI and BIP allows the DAI to dissolve more easily whilst dissuading cocrystal 
disintegration back into starting materials by the molecular interaction via BIP in solution, therefore, 
increasing the solubility of the cocrystals. The higher concentration of DAI from the cocrystals at 






Note: a) 0 mg/mL b) 2 mg/mL, c) 3.8 mg/mL, d) 4.2 mg/mL, e) 4.4 mg/mL, f) 
4.6 mg/mL, g) 4.8 mg/mL, h) 5 mg/mL, i) 5.2 g/mL, j) 6 mg/mL and k) 8 





Fig. 6: Apparent solubility of DAI in the presence of BIP at different concentrations. (a) The 
concentrations of DAI and BIP at equilibrium; (b) PXRD observations of the solid residues 
The dissolution profiles of DAI and DAI-BIP were illustrated in Fig. 7. The dissolution rate of 
DAI was significantly slower and, after 4 hours, its concentration was 2.830 ± 0.004 ug/mL. In 
contrast, the dissolution rate of DAI-BIP was greatly improved and, within 20 minutes, the 
concentration of DAI quickly reached its equilibrium solubility of 3.876±0.039 µg/mL. The 
concentration of DAI released from the cocrystal continued to increase until it reached 5.76 µg/mL, 
which was 1.49 times DAI solubility. During dissolution, a parachute effect was observed, indicating 
that the BIP might be able to maintain the supersaturated state of DAI in solution alone without the 
use of an additional precipitation inhibitor e.g. a polymer. In terms of the dissolution performance 
parameter (DPP) [35], DAI-BIP showed a 2.03-fold increase in comparison to DAI. This is due to BIP 
delivering DAI into the solution, aided by the heterosynthon, at a more rapid rate and causing a higher 
concentration at equilibrium whilst retarding the precipitation and recrystallisation of DAI out of 
solution. It was also worth noting that the solid residues, following dissolution of DAI-BIP, were 
DAI, as confirmed by PXRD (Fig S11), suggesting an occurrence of phase transformation during the 
dissolution of DAI-BIP.  
 
 
Fig. 7: Profiles of powder dissolution for DAI and DAI-BIP under non-sink conditions. 
 
4. Conclusion 
DAI has many potential therapeutic benefits which has attracted attention from scientists and 
industry. The limitation of DAI’s solubility and bioavailability can be improved by solubility 
enhancement methods such as co-crystallisation. Pyridine-derived molecules (such as nicotinamide, 




isonicotinamide and 4,4’-Bipyridine) offer an O-HNarom heterosynthon between the flavonoid and 
the pyridyl ring of the coformer. Computational screening provided an initial prediction for the 
successful preparation of novel nutraceutical cocrystal of Daidzein and 4,4’-Bipyridine (DAI-BIP) via 
grinding and solution methods. DAI-BIP belonged to the     space group of the triclinic system 
formed N4’arom∙∙∙H―O―C7 and C4’―O4―H∙∙∙N4arom intermolecular interactions between DAI and 
BIP. DAI-BIP showed increased solubility and dissolution performance in comparison to DAI. The 
solubility of DAI-BIP was 73.5-fold higher than the solubility of DAI. The dissolution rate of DAI-
BIP quickly reached its equilibrium solubility and it continued to increase till 5.76 µg/mL (1.49 times 
of the equilibrium solubility). In addition, DAI-BIP showed a 2.03-fold increase for its dissolution 
performance parameter in comparison to DAI. A parachute effect was observed during the dissolution 
of DAI-BIP, indicating a function of BIP to maintain the supersaturated state of DAI in solution 
without the addition of a polymer. It is worth noting that initial computational screening could be 
problematic and contradictive, depending on the tools used.  Therefore, experimental screening is 
always needed to discover novel cocrystals.  To the best of our knowledge, this is the first DAI 
cocrystal with the structure determined through single crystal XRD measurements which may aid the 
future discovery of more DAI cocrystals in the future for pharmaceutical applications.  
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